BioCentury | Jan 21, 2021

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures,...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...repeats and its attention to both autoimmunity and cancer. GeNeuro primarily focuses on targeting the HERVW... Phase II testing for multiple sclerosis and Type I diabetes. The mAb against the HERVW...
...issued covering therapeutic modalities and diagnostic applications of repeat sequence biology Targets HERVW (ERVW-1) - Endogenous retrovirus group W member 1...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...clinical research on hospitals was also a factor in GeNeuro's decision. The trial of the anti-HERVW...
...said it will provide updated guidance in its 1Q20 earnings report. Targets HERVW (ERVW-1) - Endogenous retrovirus group W member 1 Elizabeth...
BioCentury | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Mar 12, 2019
Clinical News

GeNeuro finds path forward for temelimab in non-active progressive MS

...funding. Temelimab is a humanized IgG4 mAb targeting the envelope protein of human endogenous retrovirus group W member 1 (HERVW; ERVW-1... also in a Phase IIa trial to treat Type I diabetes. Lauren Martz, Associate Editor GNbAC1 GeNeuro S.A. Endogenous retrovirus group W member 1 (HERVW) (ERVW-1) Multiple...
BioCentury | Sep 21, 2018
Company News

Servier declines rights to GeNeuro's GNbAC1

...endogenous retrovirus group W member 1 (HERVW; ERVW-1). GeNeuro S.A. (Euronext:GNRO), Geneva, Switzerland Servier, Neuilly-sur-Seine, France Business: Autoimmune Jaime De Leon GNbAC1 GeNeuro S.A. Servier Endogenous retrovirus group W member 1 (HERVW) (ERVW-1)...
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Jun 22, 2018
Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
Items per page:
1 - 10 of 65